Based: Rockville, MD
Stock symbol: MGNX
Range: $14 to $16
IPO price: $16
Close Oct. 17: $25.17
Change: Up 57%
Raised: $80 million

The scoop: MacroGenics only recently made its public debut, so the honeymoon period with investors is still in its earliest stages. Shares shot up 50% on the first day of trading, renewing the hope for some that the IPO window will remain open while highlighting fears of a bubble in other quarters. MacroGenics plans to spend $50 million of its IPO haul on its lead program for margetuximab, a Phase II monoclonal antibody the company believes can treat HER2-positive breast cancer. MacroGenics has another $20 million earmarked for MGA271, a Phase I immunotherapy that targets the B7-H3 regulator, which is overexpressed in a variety of solid tumors, the company said. For a company that has faced real travails in the past, the IPO win helps demonstrate that a company can overcome adversity. It will need to produce solid pivotal results to justify the stock gains, though. MacroGenics is a 2013 Fierce 15 company.

For more:
Special Report:
2013 Fierce 15 - Macrogenics
MacroGenics shares soar on glittering $80M IPO debut
MacroGenics upsizes IPO offering in bid for $92M windfall
MacroGenics trumpets cancer immunotherapies in $60M IPO pitch
On a roll, MacroGenics scoops up $10M on tumor drug milestone


Suggested Articles

With a new research team, outlook and more than a little help from the tech world, GSK has been quietly going about shoring up its pipeline.

The World Health Organization has called out Big Pharma for its dearth of antibiotic innovation amid a growing threat of antimicrobial resistance.

The trial hit its primary endpoint by the time of an interim analysis, enabling Chi-Med to stop the study and start work on a filing for approval.